SmartPeptide
Start Free
RecoveryInvestigational — no approved indicationAnimal / preclinical only

TB-500

Synthetic fragment related to thymosin beta-4. Investigated in animal studies for cellular migration and tissue remodeling.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Animal studies suggest cellular migration and tissue remodeling effects, especially in cardiac and dermal wound models.

What's still experimental

Human efficacy is essentially unproven. Safety profile in humans is undocumented in peer-reviewed RCTs.

Anecdotal / community reports

Athletic recovery claims are common in community forums but not supported by published human trials.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “TB-500”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

Source: Published clinical trial

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

Community-anecdotal range — NOT a SmartPeptide recommendation

The doses below are aggregated from research-peptide community forums (Reddit, biohacker discussions). They are NOT supported by clinical trials, NOT FDA-approved, and NOT a SmartPeptide recommendation. Source purity, dose accuracy, and user-reported outcomes are unverifiable. We display this only because the information is publicly available elsewhere — visitors should absolutely consult a licensed clinician familiar with experimental peptides before any use.

Community-anecdotal — not evidence-basedResearch-peptide community forums (uncited aggregate)
Indication studied: Research / community-discussed for tissue repair (no human RCT)
Typical
2mg(2,000 µg)
1-2x weekly during 4-6 week loading · subcutaneous

Loading phase

Open calculator
Maximum
5mg(5,000 µg)
1x weekly maintenance · subcutaneous

After loading

Open calculator

Notes from the source: No human RCT exists. Anecdotal protocols vary widely. Source purity for grey-market TB-500 is unverifiable without independent lab testing.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

How clinicians typically protocol this

Third-party reference · not our recommendation

Dosing phases, cycle lengths, and administration timing as listed in a compounding-pharmacy clinician reference guide. Shown so you can see what a real protocol looks like — and bring informed questions to a licensed clinician.

Third-party protocol referenceCompounding-pharmacy clinician protocol reference (Nov 2025)

Dose numbers, frequencies, and cycle lengths in this panel are extracted from a clinician-facing reference protocol distributed by a US-based compounding pharmacy in November 2025. SmartPeptide has paraphrased all descriptive text and adds no endorsement. Always consult a licensed clinician.

Repair

Synthetic fragment of Thymosin Beta-4; studied for regenerative and cell-migration effects.

Protocol phases

Typical
1–2 mg2× weekly (or split evenly across week)
subcutaneous

AM

Cycle length

Varies with health status; no fixed cycle in the reference.

Reported side effects
Solution may appear slightly viscous or opaque — normal, invert to redisperse
Reconstitution calculator Storage & reconstitution guide
Not medical advice. SmartPeptide does not prescribe, diagnose, or treat. The protocol above reproduces dose figures from a third-party clinician reference so you can see what compounding-pharmacy guidance typically looks like — it is not a recommendation for you, and it has not been validated against peer-reviewed dose-ranging trials. Many of these compounds are not FDA-approved for human use. Work with a licensed clinician familiar with peptide therapy before considering anything here.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “TB-500”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Known mechanisms of action
  • CHEMBL3143
    inhibitorCoagulation factor VIII inhibitor

Protein targets (UniProt)

  • Large ribosomal subunit protein bL12m
    P52815gene: MRPL12Homo sapiens· 198 aaReviewed

    As a component of the mitochondrial large ribosomal subunit, plays a role in mitochondrial translation (PubMed:23603806). When present in mitochondria as a free protein not associated with the ribosome, associates with mitochondrial RNA polymerase POLRMT to activate transcription (PubMed:22003127). Required for POLRMT stability (PubMed:26586915)

  • Large ribosomal subunit protein uL30
    Q5SHQ6gene: rpmDThermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)· 60 aaReviewed

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
1,054
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
2
18 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "thymosin beta-4"

Europe PMC — 5,208 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
7,012
all years
Last 5 years
2,456
recent activity
Open access
6,404
freely readable
OA share
91%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “thymosin beta-4” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
194
all years
Top award sum
$18.7M
aggregate USD
Years covered
20
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
187,064
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China2,364 works
  • National Institutes of Health1,090 works
  • Deutsche Forschungsgemeinschaft414 works
  • National Science Foundation371 works
  • National Research Foundation of Korea337 works
  • DOE309 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 62 preprints indexed by Europe PMC.

Known risks

Almost no human clinical data. Banned in competitive sport (WADA).

Reported side effects

Limited human safety reporting; theoretical immunomodulation concerns.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
1
FAERS, all years
Serious reports
1
100% of reports

Most-reported reactions

  • Adverse Drug Reaction
    1
  • Malignant Lymphoid Neoplasm
    1
  • Product Dispensed By Unauthorised Provider
    1

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Banned in competitive sport (WADA). Not approved for human use in most countries. Clinical supervision required if used at all.

Questions for your clinician

  • Is there any human safety data we can review?
  • Could this interact with my current medications?
  • What objective markers would we follow if we tried this?

Editorially curated references

Discussions about TB-500

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all TB-500 discussions Native, moderated, no buying or selling